SDZ 224-015

• UNSPSC Description:

  SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting Mpro (IC50 of 30 nM)[1][2].

• Target Antigen:

  Caspase; Interleukin Related; SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Apoptosis;Immunology/Inflammation

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/sdz-224-015.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(OCC1=CC=CC=C1)N[C@@H](C(C)C)C(N[C@@H](C)C(N[C@@H](CC(OCC)=O)C(COC(C2=C(C=CC=C2Cl)Cl)=O)=O)=O)=O

• Molecular Weight:

  652.52

• References & Citations:

  [1]Martin A Redhead, et al. Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. Sci Rep. 2021 Jun 24;11(1):13208.|[2]P R Elford, et al. Reduction of inflammation and pyrexia in the rat by oral administration of SDZ 224-015, an inhibitor of the interleukin-1 beta converting enzyme. Br J Pharmacol. 1995 Jun;115(4):601-6.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported

• CAS Number:

  161511-45-1